Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FTC antitrust policies should be more transparent, biomedical industry reps urge Pitofsky.

This article was originally published in The Tan Sheet

Executive Summary

FTC ANTITRUST POLICIES SHOULD BE MORE TRANSPARENT FOR BIOMEDICAL industries, an attorney suggested at an Oct. 23 meeting between pharmaceutical and biotech reps and Federal Trade Commission Chairman Robert Pitofsky. The session was part of a 10-week schedule of FTC Hearings on "Global and Innovation-Based Competition" first promised by Pitofsky at his Jan. 19 confirmation hearing. The meetings are to "evaluate whether all aspects of antitrust and consumer protection policies are up-to-date in today's world."
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS084433

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel